OTC nasal potential Amphastar is actively expanding over-the-counter nasal spray offerings for opioid overdose, following FDA approvals, presenting a clear upsell path to retailers, pharmacies, and online platforms seeking ready-to-market overdose reversal solutions.

Diversified delivery tech The company manufactures biopharmaceutical injectables, intranasal, and inhalation products across multiple US, China, and European facilities, indicating opportunities to partner on contract manufacturing, fill-finish, or co-development for diverse delivery formats.

Strategic breadth With a state-of-the-art R&D center and five manufacturing sites plus US-only finished products, Amphastar shows capacity to scale partnerships in high-quality, cGMP-compliant manufacturing, potentially benefiting suppliers of raw materials, packaging, and regulatory services.

Financial scale Revenue in the range of half a billion to one billion and substantial funding suggest readiness for new product launches or portfolio acquisitions, offering talking points for licensing deals, co-promotions, or strategic investments.

Key leadership visibility Active participation in major health conferences and executive-level engagement (CFO and EVP of Regulatory) indicates openness to investor relations, strategic partnerships, and customer-facing discussions at industry events to accelerate business development conversations.